Advertisement
"Alan has the unique talent to integrate the science of discovery with newdrug development -- a critical asset that will deepen Novo Nordisk'sleadership position in changing diabetes," said Mads Krogsgaard Thomsen,executive vice president and chief science officer for Novo Nordisk A/S. "Thebroadening of Novo Nordisk's diabetes therapeutic portfolio with thedevelopment of liraglutide and other novel molecules in the pipeline, and theincreasing importance of the U. S. to the Novo Nordisk business, requires aleader with clinical and research expertise to assume the role of chiefmedical officer."
Advertisement
In the newly expanded role, Moses will work closely with senior colleaguesin Denmark to serve as the principle voice of clinical science for the companyworldwide, providing clinical and medical affairs expertise.
"Novo Nordisk and the diabetes community in the U.S. have been fortunateto have Alan lead the efforts for the company in changing diabetes, and now,with his expanded responsibilities, the world will benefit from Alan's passionfor research and advocacy for finding better ways for people to live with thedisease," said Dr. Henrik Rasmussen, vice president of clinical development,medical and regulatory affairs, Novo Nordisk Inc.
Moses was formerly senior vice president and chief medical officer at theJoslin Diabetes Center and joined Novo Nordisk in April 2004 as associate vicepresident of medical affairs and since then has also assumed responsibilityfor clinical research in diabetes. Prior to joining Novo Nordisk, Dr. Mosesspent 23 years at Harvard Medical School-affiliated institutions where he roseto the rank of Professor of Medicine. He has written more than 100 peer-reviewed articles on the treatment of diabetes and has been recognized bothlocally and nationally for his research in diabetes and growth factors.
Moses received a Bachelor of Science from Duke University and a MedicalDoctorate from Washington University School of Medicine prior to training atBarnes Hospital in St. Louis, the National Institutes of Health in Bethesda,Md., and Tufts-New England Medical Center in Boston. He is board certified bythe American Board of Internal Medicine and has a subspecialty certificationin Endocrinology and Metabolism.
About Novo Nordisk
Novo Nordisk is a healthcare company with an 84-year history of innovationand achievement in diabetes care. The company has the broadest diabetesproduct portfolio in the industry, including the most advanced products withinthe area of insulin delivery systems. In addition to diabetes care, NovoNordisk has a leading position within areas such as hemostasis management,growth hormone therapy, and hormone therapy for women. Novo Nordisk's businessis driven by the Triple Bottom Line: a commitment to economic success,environmental soundness, and social responsibility to employees and customers.With headquarters in Denmark, Novo Nordisk employs more than 25,800 employeesin 79 countries, and markets its products in 179 countries. Novo Nordisk's Bshares are listed on the stock exchanges in Copenhagen and London. Its ADRsare listed on the New York Stock Exchange under the symbol 'NVO'. For globalinformation, visit novonordisk.com; for United States information, visitnovonordisk-us.com.
SOURCE Novo Nordisk
